Pharmaceutical R&D: Costs, Risks and Rewards : Summary, Seite 49

DIANE Publishing, 1993 - 41 Seiten
Analyzes the costs, risks, and economic rewards of pharmaceutical R&D and the impact of public policy on both costs and returns. Examines the rapid increase in pharmaceutical R&D that began in the 1980s in the light of trends in science, technology, drug discovery, and health insurance coverage; Government regulation; product liability; market competition; Federal tax policy; and Federal support of prescription drug research. 12 appendices, including a glossary of terms.

Im Buch

Andere Ausgaben - Alle anzeigen

Häufige Begriffe und Wortgruppen

Beliebte Passagen

Seite 207 - In basic research the objective of the sponsoring agency is to gain fuller knowledge or understanding of the fundamental aspects of phenomena and of observable facts without specific applications toward processes or products in mind.
Seite 135 - biological product" as "any virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product or analogous product ' ' * applicable to the prevention, treatment, or cure of diseases or injuries of man...
Seite 118 - Identification of the cystic fibrosis gene: genetic analysis. Science. 1989;245: 1073-1080. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.
Seite 210 - NIH National Institutes of Health NIMH National Institute of Mental Health NINDS National Institute of Neurological Disorders and Stroke...
Seite 181 - research or experimental expenditures", as used in section 174, means expenditures incurred in connection with the taxpayer's trade or business which represent research and development costs in the experimental or laboratory sense. The term includes generally all such costs incident to the development of an experimental or pilot model, a plant process, a product, a formula, an invention, or similar property, and the improvement of already existing property of the type mentioned.
Seite 328 - Department of Health and Human Services Public Health Service Food and Drug Administration Rockville, MD 20857 Official Business Penalty for Private Use S300 BUSINESS REPLY MAIL FIRST CLASS MAIL PERMIT NO.
Seite 280 - Competitive Problems in the Drug Industry. Hearings before the Subcommittee on Monopoly of the Select Committee on Small Business...
Seite 284 - Respondents also contend that the subpoena cannot be protected by the speech or debate immunity because the "sole purpose" of the investigation is to force "public disclosure of beliefs, opinions, expressions and associations of private citizens which may be unorthodox or unpopular.
Seite 221 - Institute NIA - National Institute on Aging NIAAA - National Institute on Alcohol Abuse and Alcoholism NIAID - National Institute of Allergy and Infectious Diseases NIAMS - National Institute of Arthritis and Musculoskeletal and Skin Diseases NICHD - National Institute of Child Health and Human Development NIDA - National Institute on Drug Abuse...

Bibliografische Informationen